Table 2

Autoantibodies and drug-induced lupus under infliximab

New ANA

New anti-dsDNA

New ACLA




Diagnosis

Number

Positive

Positivea

IgM

IgG

IgM

IgG

DIL

Reference


RA

156

37 (24%)

22 (14%)

22

1

ND

ND

1

[20]

RA

62

19 (31%)

7 (11%)

7

0

ND

ND

0

[22]

RA

24

4 (17%)

13 (54%)

9–11

3–4

5

0

0

[24]

RA

59

24 (41%)

21 (36%)

19

2

ND

ND

0

[26]

RA

53

29 (55%)

5 (9%)

22b

34b

0

0

2

[27]

RA

59

24 (41%)

29 (49%)

28

1

0

0

0

[28]

RA

57

28 (49%)

ND

3

ND

ND

1

[31]

All RA

413

165 (40%)

77 (19%)

4 (1.0%)

AS

15

9 (60%)

4 (27%)

4

0–1

1

3

0

[24]

SpA

21

12 (57%)

4 (19%)

ND

ND

ND

ND

0

[21]

SpA

35

25 (71%)

6 (17%)

6

0

ND

ND

0

[22]

SpA

33

8 (24%)

11 (33%)

11

0

ND

ND

0

[29]

All SpA

94

54 (57%)

25 (27%)

0 (0%)

CD

35

6 (17%)

3 (9%)

ND

ND

ND

ND

0

[23]

CD

125

71 (57%)

14 (11%)

ND

ND

ND

ND

2

[25]

CD

500

ND

ND

ND

ND

ND

ND

3

[35]

CD

63

21 (33%)

9 (14%)

ND

9

2

0

1

[30]

All CD

723

6 (0.8%)

All together

1,230

10 (0.8%)


aRadioimmunoassay or most conservative value reported; bvalues difficult to reconcile with the number of patients with anti-dsDNA antibodies as measured by radioimmunoassay. ACLA, anti-cardiolipin antibodies; ANA, anti-nuclear antibodies; anti-dsDNA, antibodies to double-stranded DNA; AS, ankylosing spondylitis; CD, Crohn disease; DIL, drug-induced lupus; Ig, immunoglobulin; ND, not determined/reported; RA, rheumatoid arthritis; SpA, spondylarthropathies.

Aringer and Smolen Arthritis Research & Therapy 2008 10:202   doi:10.1186/ar2341